Oxford PharmaGenesis awarded business accolade

GSK has announced changes to its sales representative incentive programme for representatives in certain countries

Independent HealthScience communications consultancy Oxford PharmaGenesis has been awarded its second Queen’s Award for Enterprise, the UK’s highest accolade for business success.

The consultancy was recognised for the second time in the category ‘Outstanding Achievement in International Trade’. Since winning its last award in 2015, the company’s total annual sales have more than doubled from £10 million to over £21 million.

In the past year, Oxford PharmaGenesis has been the only company in the sector to be named for a second time in the ‘1000 Companies to Inspire Britain’ report from the London Stock Exchange Group. Also, for the second time, it has been named as a member of the Alantra Pharma Fast 50, which recognises the fastest-growing, independently owned pharmaceutical and technology companies in the UK.

Group Communications Director Dr Andy Sheridan said: “This doesn’t just happen by chance: it happens because of the tremendous teamwork of the excellent people we have recruited and trained throughout our organisation, and the fantastic support we receive from our clients around the world.”

CEO Dr Chris Winchester said: “Our mission is to help our clients bring new treatments to patients in areas of unmet medical need. What more satisfying objective could there be? We are not part of a larger group driven purely by financial targets, and we have found that doing things our way not only brings business success and a fast pace of organic growth but is also immensely satisfying.”

COO Dr Richard White added: “We care most about the patients we ultimately serve and we can only do this by being a successful business, so it is great to receive external validation of our work.”